(12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(19) World Intellectual Property Organization
International Bureau

(43) International Publication Date
16 April 2015 (16.04.2015)

WIPO | PCT

(10) International Publication Number
WO 2015/052537 A1

(51) International Patent Classification:
C07K 16/28 (2006.01) *C07K 16/30* (2006.01)
A61K 47/48 (2006.01) *A61K 39/00* (2006.01)

(21) International Application Number:
PCT/GB2014/053057

(22) International Filing Date:
10 October 2014 (10.10.2014)

(25) Filing Language: English

(26) Publication Language: English

(30) Priority Data:
61/890,098 11 October 2013 (11.10.2013) US
61/890,104 11 October 2013 (11.10.2013) US

(71) Applicant: **OXFORD BIOTHERAPEUTICS LTD** [GB/GB]; 94A Innovation Drive, Milton Park, Abingdon Oxfordshire OX14 4RZ (GB).

(72) Inventors: **TERRETT, Jonathan Alexander**; Oxford BioTherapeutics Inc, San Jose Biocenter, 5941 Optical Court, San Jose, California CA 95138 (US). **ACKROYD, James Edward**; 94A Innovation Drive, Miton Park, Abigdon Oxfordshire OX14 4RZ (GB).

(74) Agent: **BLANCE, Stephen**; 94A Innovation Drive, Milton Park, Abingdon Oxfordshire OX14 4RZ (GB).

(81) Designated States *(unless otherwise indicated, for every kind of national protection available)*: AE, AG, AL, AM, AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY, BZ, CA, CH, CL, CN, CO, CR, CU, CZ, DE, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IR, IS, JP, KE, KG, KN, KP, KR, KZ, LA, LC, LK, LR, LS, LU, LY, MA, MD, ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PA, PE, PG, PH, PL, PT, QA, RO, RS, RU, RW, SA, SC, SD, SE, SG, SK, SL, SM, ST, SV, SY, TH, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW.

(84) Designated States *(unless otherwise indicated, for every kind of regional protection available)*: ARIPO (BW, GH, GM, KE, LR, LS, MW, MZ, NA, RW, SD, SL, ST, SZ, TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, RU, TJ, TM), European (AL, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV, MC, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, KM, ML, MR, NE, SN, TD, TG).

Published:

— *with international search report (Art. 21(3))*

— *with sequence listing part of description (Rule 5.2(a))*

WO 2015/052537 A1

(54) Title: CONJUGATED ANTIBODIES AGAINST LY75 FOR THE TREATMENT OF CANCER

(57) Abstract: The invention provides antibodies which bind to LY75. Nucleic acid molecules encoding the antibodies, expression vectors, host cells and methods for expressing the antibodies are also provided. The antibodies may be used for the treatment of cancer, including pancreatic cancer, ovarian cancer, breast cancer, colorectal cancer, esophageal cancer, skin cancer, thyroid cancer, lung cancer, bladder cancer, multiple myeloma and lymphoma.